Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02008877 · ClinicalTrials.gov registry record · Phase 1
SARC023: Ganetespib and Sirolimus in Patients With MPNST (Malignant Peripheral Nerve Sheath Tumors)
A Phase 1 study, sponsored by Sarcoma Alliance for Research through Collaboration.
- Completed
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
NCT02008877 is a Phase 1 study that has completed, run by Sarcoma Alliance for Research through Collaboration. The registered enrollment target is 20 participants.
The verdict
NCT02008877, a Phase 1 study, has completed, sponsored by Sarcoma Alliance for Research through Collaboration.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
Study Summary
Phase 1: To assess the safety, tolerability, and maximum tolerated dose (MTD)/ recommended dose of ganetespib when administered in combination with sirolimus in patients with refractory or relapsed sarcomas including unresectable or metastatic sporadic or neurofibromatosis type 1 (NF1) associated MPNST. Phase I enrollment has been closed. Phase 2: To determine the clinical benefit of ganetespib in combination with sirolimus for patients with unresectable or metastatic sporadic or NF1 associated MPNST.
Interventions
- DRUG Sirolimus
- DRUG ganetespib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2013-12 |
| Est. Completion | 2018-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02008877
The ClinicalTrials.gov registry entry for NCT02008877 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sarcoma Alliance for Research through Collaboration, which has 20 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Sirolimus is the first listed.
NCT02008877 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02008877 about?
NCT02008877 is a clinical study titled "SARC023: Ganetespib and Sirolimus in Patients With MPNST (Malignant Peripheral Nerve Sheath Tumors)". Phase 1: To assess the safety, tolerability, and maximum tolerated dose (MTD)/ recommended dose of ganetespib when administered in combination with sirolimus in patients with refractory or relapsed sarcomas including unresectable or metastatic sporadic or neurofibromatosis type 1 (NF1) associated MP...
What is the current status of trial NCT02008877?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2013-12. Estimated completion is 2018-07.
What interventions are being tested in trial NCT02008877?
The interventions under investigation include: Sirolimus (DRUG), ganetespib (DRUG).
Who is sponsoring clinical trial NCT02008877?
This trial is sponsored by Sarcoma Alliance for Research through Collaboration, which has 20 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.